Last update 04 Nov 2024

Lusutrombopag

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lusutrombopag (JAN/USAN/INN), RSC888711, S-888711
+ [4]
Mechanism
TPO receptor agonists(Thrombopoietin receptor agonists)
Active Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
JP (28 Sep 2015),
RegulationFast Track (US)
Login to view timeline

Structure

Molecular FormulaC29H32Cl2N2O5S
InChIKeyNOZIJMHMKORZBA-KJCUYJGMSA-N
CAS Registry1110766-97-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Thrombocytopenia
JP
28 Sep 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic liver diseasePhase 3-15 Jun 2015
Chronic thrombocytopeniaPhase 2
US
29 Apr 2010
Purpura, Thrombocytopenic, IdiopathicPhase 2
US
18 Mar 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
66
pdtxvemiwo(wzkityslfp) = wgxxwlujpy wizlzhwilp (llfbybhmfo )
Positive
18 Oct 2022
Placebo
pdtxvemiwo(wzkityslfp) = tidtwtmmcp wizlzhwilp (llfbybhmfo )
Phase 3
215
zlxvszjfqa(nffgxywhwb) = One patient from the phase 1/2 study had a non-serious portal vein thrombosis, which was not considered treatment-related zbtwghsusn (bgoewzrgxk )
-
29 Jul 2022
Phase 2
19
jedtqnczhb(hgvyxyegbp) = vciuywhizg wbawdwhazq (uzfgzmvwxs, xbkbapyzdi - eolkqduyzs)
-
26 Feb 2021
Phase 2
20
Placebo
(Placebo)
grmmslowna(njkspxdbbc) = xhelkhcvee dvlwfhotgg (opffazgjzz, dqxhbexbsw - cxkhjazaax)
-
24 Feb 2021
(Lusutrombopag 0.5 mg)
grmmslowna(njkspxdbbc) = uvsonisjfx dvlwfhotgg (opffazgjzz, gceeffipuy - cbdxrvlhkr)
Phase 1
8
ujweatgklp(dnypwqlmeq) = fszjeedcwb kgcugyynkq (qcfeotbuio )
-
10 Jun 2019
Not Applicable
-
zrnwfnpqvg(obszncqubo) = Lower BE rates, regardless of severity and timing of onset, were observed for LUSU alone vs PBO+PT. Percent of pts with BE was numerically higher with PBO+PT vs LUSU alone, both during (4.8% vs 3.2%) and post-procedure (7.1% vs 4.0%). Percent of pts with BE in liver-related procedures was greater in the PBO+PT arm (16.1%) vs LUSU alone (11.1%), and a larger difference was seen with gastrointestinal-related procedures in PBO+PT (8.9%) vs LUSU alone (2.0%) wcmscyqyoe (hullassbmg )
-
13 Apr 2019
Placebo+Platelet Transfusion
Phase 3
215
(Lusutrombopag)
koykalobpx(hrtgvusdoc) = jenvqjdvlk pmeadeppwy (wrubvuyilm, kfblfurzec - kecmjvpmdu)
-
25 Sep 2018
Placebo
(Placebo)
koykalobpx(hrtgvusdoc) = msfeiburkn pmeadeppwy (wrubvuyilm, camcbcmwpk - ipqpurkmmo)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free